Literature DB >> 4020828

Vinblastin-23-oyl amino acid derivatives: chemistry, physicochemical data, toxicity, and antitumor activities against P388 and L1210 leukemias.

K S Bhushana Rao, M P Collard, J P Dejonghe, G Atassi, J A Hannart, A Trouet.   

Abstract

The dimeric alkaloids vinblastine (VLB) and vincristine (VCR) differ structurally only in the functional group on the dihydroindole nitrogen. The semisynthetic derivative vindesine (VDS) differs slightly from VLB by having an amide group instead of an ester group. However, these minor distinctions are responsible for profound differences in the oncolytic spectrum, potency, and toxicity of these compounds. Vinblastin-23-oyl amino acid derivatives were synthesized by linking amino acid carboxylic esters to the vinblastin-23-oyl moiety through an amide linkage. Studies were extended to explore the influence of the nature of the amino acid, the ester alkyl chain lengths, the stereoisomerism of the amino acid, or the reacetylation of the hydroxyl group (position O-4) of the vindoline moiety. The present study deals with the synthesis of 21 vinblastin-23-oyl amino acid derivatives, some of their physicochemical data, the acute toxicity in mice, and therapeutic activities of these derivatives against the P388 and L1210 leukemias in comparison with VDS, VBL, and VCR.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4020828     DOI: 10.1021/jm00146a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  A phase I study of vinblastine tryptophan ester.

Authors:  F Ceulemans; Y Humblet; A Bosly; M Symann; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 2.  Modifications on the basic skeletons of vinblastine and vincristine.

Authors:  Péter Keglevich; László Hazai; György Kalaus; Csaba Szántay
Journal:  Molecules       Date:  2012-05-18       Impact factor: 4.411

3.  The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts.

Authors:  E Boven; H R Hendriks; C A Erkelens; H M Pinedo
Journal:  Br J Cancer       Date:  1992-12       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.